医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批

药融链接2025-12-15

本期看点：复宏汉霖核心产品斯鲁利单抗新适应症申报获优先审评，审评进度有望加速。君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。药监政策动态频出，进口食药物质管理试点与多项药品标准更新引关注。点击立即报名2025年12月15日药融链接医药日报01药政动态管理措施试点：海关总署、国家卫健委、市场监管总局及国家药监局联合发布公告，将开展进口食品和药品物质分类管理试点。说明书修订：国家药监局...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2591649007?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-12-15 17:06","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2591649007","market":"hk","top_or_hot":-1,"title":"医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批","media":"药融链接","content":"<div>\n<p>本期看点：复宏汉霖核心产品斯鲁利单抗新适应症申报获优先审评，审评进度有望加速。君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。药监政策动态频出，进口食药物质管理试点与多项药品标准更新引关注。点击立即报名2025年12月15日药融链接医药日报01药政动态管理措施试点：海关总署、国家卫健委、市场监管总局及国家药监局联合发布公告，将开展进口食品和药品物质分类管理试点。说明书修订：国家药监局...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n医药日报：复宏汉霖新适应症获优先审评，君实生物双抗ADC出海获批\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-15 17:06 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b><strong>药融链接</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>本期看点：复宏汉霖核心产品斯鲁利单抗新适应症申报获优先审评，审评进度有望加速。君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。药监政策动态频出，进口食药物质管理试点与多项药品标准更新引关注。点击立即报名2025年12月15日药融链接医药日报01药政动态管理措施试点：海关总署、国家卫健委、市场监管总局及国家药监局联合发布公告，将开展进口食品和药品物质分类管理试点。说明书修订：国家药监局...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","article_id":"2591649007","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215175631a44d99ba&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2591649007","pubTimestamp":1765789608,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。02产品注册与审批复宏汉霖：其产品斯鲁利单抗注射液新增适应症的上市申请已获受理，并被纳入优先审评程序。04国际合作与出海君实生物：其针对EGFR/HER3的双特异性抗体偶联药物用于治疗晚期实体瘤的临床试验申请，已获得美国FDA批准。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","01877":"君实生物","HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","02696":"复宏汉霖","BK1583":"高瓴概念","BK1515":"抗疫概念"},"translate_title":"Pharmaceutical Daily: Henlius' new indications received priority review, and Junshi Bio's double antibody ADC was approved to go overseas","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02696":1.5,"09939":1.5,"01877":1.5},"content_text":"本期看点：复宏汉霖核心产品斯鲁利单抗新适应症申报获优先审评，审评进度有望加速。君实生物双抗ADC获FDA临床试验批准，国际化研发取得新进展。药监政策动态频出，进口食药物质管理试点与多项药品标准更新引关注。点击立即报名2025年12月15日药融链接医药日报01药政动态管理措施试点：海关总署、国家卫健委、市场监管总局及国家药监局联合发布公告，将开展进口食品和药品物质分类管理试点。说明书修订：国家药监局决定对更年安制剂及复方当归注射剂的药品说明书进行修订。标准立项征集：国家药典委员会正公开征集2026年国家药品标准制修订项目的潜在承担单位。检测方法公示：国家药典委员会公布了《3410 抗补体活性测定法》的标准草案，面向公众征求意见。02产品注册与审批复宏汉霖：其产品斯鲁利单抗注射液新增适应症的上市申请已获受理，并被纳入优先审评程序。康缘药业：成功获得中药新药“泻白散颗粒”的药品注册证书。天津市中央药业：申报的阿普米司特片上市许可申请已获批，适用于银屑病患者。滨海美康药业：利丙双卡因乳膏获批获得药品注册证书。北陆药业：格列酮二甲双胍片获发药品注册证书，该品种被视为通过仿制药质量和疗效一致性评价。一品红：旗下产品芩香清解口服液获批准成为国家中药二级保护品种。03研发与临床进展诺诚健华：其BTK抑制剂奥布替尼用于治疗系统性红斑狼疮的III期临床试验申请获得批准。来凯医药：其AKT抑制剂LAE002（afuresertib）联合疗法针对乳腺癌的III期临床试验已完成患者入组。苏州盛迪亚：其创新药物SHR-A1811（皮下注射）注射液获准开展单药治疗晚期实体瘤的临床试验。福建盛迪医药：HRS9531注射液获批准开展针对代谢相关脂肪性肝炎（MASH）的临床试验。瑞石生物医药：RSS0343片获准开展临床试验，适应症为慢性鼻窦炎不伴鼻息肉和慢性阻塞性肺疾病。山东盛迪医药：HRS-1780片获准开展用于心力衰竭患者的临床试验。沃森生物：其子公司研发的冻干带状疱疹病毒mRNA疫苗的临床试验申请获得批准。04国际合作与出海君实生物：其针对EGFR/HER3的双特异性抗体偶联药物（ADC）用于治疗晚期实体瘤的临床试验申请，已获得美国FDA批准。海正药业：其子公司生产的依维莫司原料药成功获得欧洲药典适用性认证（CEP）证书。百奥泰：其生物类似药戈利木单抗注射液获得欧洲药品管理局（EMA）人用药品委员会（CHMP）的积极审评意见。01论坛议程1月16日会场二：原料药企业内卷破局之路论坛09:00-09:40原料药企业内卷破局之路王宜运新华制药研究院副院长09:40-10:20生物合成原料的研发注册关键事项李银博悉咨医药 联合创办人10:20-10:40茶歇10:40-11:20制造”到“智造”：原料药企业的价值跃迁之路嘉宾行程确认中11:20-12:00原料药-制剂一体化下的供应链协同与运营效率提升嘉宾行程确认中*议程更新中，以会议现场为准扫码免费报名参会商务合作","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2591649007","isCrawlerRequest":true}